ArticleCureus2025
Early Massive Left Atrial Thrombosis Following Mitral Bioprosthetic Valve Replacement Due to Suboptimal Anticoagulation: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial thrombi are rare after mitral valve replacement. We report a case of early postoperative massive left atrial thrombus following bioprosthetic mitral valve replacement. The patient, a 61-year-old woman, underwent mitral valve replacement, tricuspid ring annuloplasty, and left atrial plication and was discharged after achieving the target international normalized ratio (INR) with oral warfarin. At the two-month follow-up, the imaging findings indicated a giant left atrial thrombus measuring 79 × 55 × 45 mm, with a subtherapeutic INR of 1.18. Anticoagulation therapy was intensified with warfarin and bridged with subcutaneous nadroparin. The thrombus decreased after three weeks and resolved completely by three months, and subsequent echocardiography showed valvular function was satisfactory. This case underscores the importance of strict INR monitoring for high-risk patients, highlighting that warfarin is an effective treatment option for left atrial thrombi following mitral valve replacement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.